塞来昔布对慢性粒细胞白血病原代细胞bcr—abl融合蛋白的影响  

Effects of celecoxib on bcr-abl fusion protein in chronic myeloid leukemia primary cells

作　　者：刘定胜[1] 李玉峰[1] 李敏[2] 丁邦和[1] 朱家斌[1] 何正梅[1] 

机构地区：[1]南京医科大学附属淮安第一医院血液科,223300 [2]南京医科大学附属淮安第一医院感染科,223300

出　　处：《白血病．淋巴瘤》2011年第1期49-51,共3页Journal of Leukemia & Lymphoma

基　　金：南京医科大学科技发展基金（07NMUZ039）;淮安市科技发展计划（HAS07034）

摘　　要：目的 探讨塞来昔布对慢性粒细胞向血病（CML）原代细胞her—abl融合基因的mRNA表达、p210蛋白表达和蛋白质酪氨酸激酶（PTK）活性的影响：方法 以不同浓度的塞来昔布（0、10、20、40、80、160μmol／L）分别干预CML原代细胞36h．进行荧光实时定奄反转录聚合酶链反应（RQ—RT—PCR）、Western blotting和PTK活性检测。结果80～160μmol／L的塞来昔布下调ber-abl的mRNA表达；随着塞来昔布浓度增加，p210蛋白表达逐步下渊；40μmol／L，以上的塞来昔布能明显抑制PTK活性，但非浓度依耐性：结论塞米昔布能不同程度地下调CML原代细胞her—abl的mRNA和蛋白表达，并抑制PTK活性．Objective To explore the effects of celecoxib, a cyclooxygenase-2 （COX-2） specific inhibitor, on the mRNA expression protein expression and protein tyrosine kinase （PTK） activity of bcr-abl fusion gene in chronic mye]oid leukemia （CML） primaly cells. Methods The primary cells were incubated with various concentration of celeeoxib （0, 10, 20, 40. 80, 160 μmol/L） for 36 hours, then the changes of mRNA expression, p210 expression and PTK activity of ber-abl fusion gene in each group were examined respectively by real time quantilative reverse traoseriptase polymerase chain reaction （RQ-RT-PCR）, Western blotting and PTK activity analysis. Results The mRNA expression was downregulated with high concentration of celecoxib （80-160 μmol/L）, and p210 expression was decreased gradually after increasing celecoxib. The PTK activity was inhibited in a concentration-independent way, and the statistic difference was observed only above 40 μmol/L eoncentration of celecoxih. Conclusion Celecoxib ean downregalate mRNA, and the protein expression of ber-abl fusion gene; and inhibit the PTK activty by defferent extent.

关 键 词：白血病 髓样 慢性 塞来昔布 环氧化酶2抑制剂 融合蛋白质类 ber-abl 

分 类 号：R733.72[医药卫生—肿瘤]